Zacks: Analysts Expect Adaptimmune Therapeutics PLC – (ADAP) to Announce -$0.03 EPS

Equities analysts forecast that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will report earnings of ($0.03) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at $0.26. The company is expected to issue its next earnings results on Thursday, November 1st.

On average, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.02) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($0.68). For the next year, analysts anticipate that the business will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%.

A number of research analysts have issued reports on ADAP shares. BidaskClub raised shares of Adaptimmune Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 24th. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, August 2nd. Guggenheim started coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They set a “buy” rating on the stock. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, ValuEngine raised shares of Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.33.

In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $13.79, for a total value of $344,750.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ali Behbahani bought 12,000,000 shares of Adaptimmune Therapeutics stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $20,040,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $122,000. BB&T Securities LLC purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $128,000. Raymond James Financial Services Advisors Inc. grew its position in Adaptimmune Therapeutics by 70.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 13,151 shares during the last quarter. Jane Street Group LLC purchased a new stake in Adaptimmune Therapeutics during the 1st quarter valued at about $168,000. Finally, Trexquant Investment LP purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $178,000. 59.32% of the stock is currently owned by institutional investors.

Shares of Adaptimmune Therapeutics stock opened at $10.88 on Tuesday. Adaptimmune Therapeutics has a 12-month low of $6.60 and a 12-month high of $14.63.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply